NCT00170573View on ClinicalTrials.gov

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2009

Study Completion Date

August 31, 2010

Conditions
Ovarian Cancer
Interventions
DRUG

Caelyx

40 mg/m² biweekly

All Listed Sponsors
lead

North Eastern German Society of Gynaecological Oncology

OTHER

NCT00170573 - Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter